FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313646952> ?p ?o ?g. }

• W4313646952 endingPage "362" @default.
• W4313646952 startingPage "362" @default.
• W4313646952 abstract "Pathological complete response (pCR) after neoadjuvant systemic treatment (NST) is an important prognostic factor in HER2-positive breast cancer. The majority of HER2-positive breast cancers are amplified at the HER2 gene locus, several genes are co-amplified with HER2, and a subset of them are co-expressed. The STARD3 gene belongs to the HER2 amplicon, and its role as a predictive marker was never addressed. The objective of this study was to investigate the predictive value of STARD3 protein expression on NST pathological response in HER2-positive breast cancer. In addition, we studied the prognostic value of this marker. Methods. We conducted a retrospective study between 2007 and 2020 on 112 patients with non-metastatic HER2-positive breast cancer treated by NST and then by surgery. We developed an immunohistochemistry assay for STARD3 expression and subcellular localization and determined a score for STARD3-positivity. As STARD3 is an endosomal protein, its expression was considered positive if the intracellular signal pattern was granular. Results: In this series, pCR was achieved in half of the patients. STARD3 was positive in 86.6% of cases and was significantly associated with pCR in univariate analysis (p = 0.013) and after adjustment on other known pathological parameters (p = 0.044). Performances on pCR prediction showed high sensitivity (96%) and negative predictive value (87%), while specificity was 23% and positive predictive value was 56%. Overall, specific, relapse-free, and distant metastasis-free survivals were similar among STARD3 positive and negative groups, independently of other prognosis factors. Conclusion: NST is an opportunity for HER2-positive cancers. In this series of over a hundred HER2-positive and non-metastatic patients, a STARD3-negative score was associated with the absence of pathological complete response. This study suggests that determining STARD3 overexpression status on initial biopsies of HER2-positive tumors is an added value for the management of a subset of patients with high probability of no pathological response." @default.
• W4313646952 created "2023-01-07" @default.
• W4313646952 creator A5021887762 @default.
• W4313646952 creator A5037566684 @default.
• W4313646952 creator A5050635753 @default.
• W4313646952 creator A5051372625 @default.
• W4313646952 creator A5052450141 @default.
• W4313646952 creator A5069801356 @default.
• W4313646952 creator A5082200467 @default.
• W4313646952 creator A5090700924 @default.
• W4313646952 date "2023-01-05" @default.
• W4313646952 modified "2023-09-30" @default.
• W4313646952 title "STARD3: A New Biomarker in HER2-Positive Breast Cancer" @default.
• W4313646952 cites W1830592026 @default.
• W4313646952 cites W1963587806 @default.
• W4313646952 cites W1981173973 @default.
• W4313646952 cites W1987326983 @default.
• W4313646952 cites W1987642949 @default.
• W4313646952 cites W1998032903 @default.
• W4313646952 cites W2005284206 @default.
• W4313646952 cites W2006070721 @default.
• W4313646952 cites W2006253236 @default.
• W4313646952 cites W2015725271 @default.
• W4313646952 cites W2020541351 @default.
• W4313646952 cites W2022166639 @default.
• W4313646952 cites W2027944956 @default.
• W4313646952 cites W2036726452 @default.
• W4313646952 cites W2040935952 @default.
• W4313646952 cites W2043398720 @default.
• W4313646952 cites W2043506695 @default.
• W4313646952 cites W2044433401 @default.
• W4313646952 cites W2044702943 @default.
• W4313646952 cites W2045413188 @default.
• W4313646952 cites W2047034979 @default.
• W4313646952 cites W2048284906 @default.
• W4313646952 cites W2055235037 @default.
• W4313646952 cites W2077515948 @default.
• W4313646952 cites W2086486491 @default.
• W4313646952 cites W2093602965 @default.
• W4313646952 cites W2096283457 @default.
• W4313646952 cites W2110782761 @default.
• W4313646952 cites W2117692326 @default.
• W4313646952 cites W2143564454 @default.
• W4313646952 cites W2146384083 @default.
• W4313646952 cites W2149626514 @default.
• W4313646952 cites W2153117051 @default.
• W4313646952 cites W2157425241 @default.
• W4313646952 cites W2158414019 @default.
• W4313646952 cites W2169344919 @default.
• W4313646952 cites W2169351080 @default.
• W4313646952 cites W2201588237 @default.
• W4313646952 cites W2560367415 @default.
• W4313646952 cites W2599076725 @default.
• W4313646952 cites W2604801873 @default.
• W4313646952 cites W2766318992 @default.
• W4313646952 cites W2771978163 @default.
• W4313646952 cites W2774227900 @default.
• W4313646952 cites W2806074020 @default.
• W4313646952 cites W2892287597 @default.
• W4313646952 cites W2896084151 @default.
• W4313646952 cites W2899659781 @default.
• W4313646952 cites W2916749426 @default.
• W4313646952 cites W2955877542 @default.
• W4313646952 cites W2996630100 @default.
• W4313646952 cites W2998950563 @default.
• W4313646952 cites W2999400187 @default.
• W4313646952 cites W3153297344 @default.
• W4313646952 cites W3153619412 @default.
• W4313646952 cites W3160666703 @default.
• W4313646952 cites W3162350134 @default.
• W4313646952 cites W4211005384 @default.
• W4313646952 cites W4226051140 @default.
• W4313646952 cites W4281675214 @default.
• W4313646952 cites W4292229870 @default.
• W4313646952 cites W4307897185 @default.
• W4313646952 doi "https://doi.org/10.3390/cancers15020362" @default.
• W4313646952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36672312" @default.
• W4313646952 hasPublicationYear "2023" @default.
• W4313646952 type Work @default.
• W4313646952 citedByCount "2" @default.
• W4313646952 countsByYear W43136469522023 @default.
• W4313646952 crossrefType "journal-article" @default.
• W4313646952 hasAuthorship W4313646952A5021887762 @default.
• W4313646952 hasAuthorship W4313646952A5037566684 @default.
• W4313646952 hasAuthorship W4313646952A5050635753 @default.
• W4313646952 hasAuthorship W4313646952A5051372625 @default.
• W4313646952 hasAuthorship W4313646952A5052450141 @default.
• W4313646952 hasAuthorship W4313646952A5069801356 @default.
• W4313646952 hasAuthorship W4313646952A5082200467 @default.
• W4313646952 hasAuthorship W4313646952A5090700924 @default.
• W4313646952 hasBestOaLocation W43136469521 @default.
• W4313646952 hasConcept C121608353 @default.
• W4313646952 hasConcept C126322002 @default.
• W4313646952 hasConcept C142724271 @default.
• W4313646952 hasConcept C143998085 @default.
• W4313646952 hasConcept C144301174 @default.
• W4313646952 hasConcept C204232928 @default.
• W4313646952 hasConcept C207886595 @default.

• next